# The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer

> **NCT05555901** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 116 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib+ chemotherapy
- **DRUG:** Bevacizumab+ chemotherapy

## Key facts

- **NCT ID:** NCT05555901
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-18
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2023-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05555901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05555901, "The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05555901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*